Can post-mar­ket ev­i­dence gen­er­a­tion be stream­lined? FDA-com­mis­sioned re­port pro­pos­es so­lu­tions

As the FDA seeks to bring a greater fo­cus to im­prov­ing post-mar­ket ev­i­dence gen­er­a­tion, a new re­port from the Rea­gan-Udall Foun­da­tion of­fers some po­ten­tial so­lu­tions to the sys­tem it says is too cost­ly and com­pli­cat­ed.

The Rea­gan-Udall Foun­da­tion of­fered more than two dozen rec­om­men­da­tions for im­prov­ing post-mar­ket ev­i­dence gen­er­a­tion sys­tems, in­clud­ing sim­pli­fy­ing pro­to­col ob­jec­tives and in­creas­ing pa­tient in­volve­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER